Showing results (121-130 of 138) with videos related to
Sort By:
Pageof 14
General Thoracic and Cardiovascular Surgery|March 13, 2009
Histoculture drug response assay for gefitinib in non-small-cell lung cancerTatsuya Yoshimasu, Fuminori Ohta, Shoji Oura, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 18, 2011
Epidermal growth factor receptor mutations are associated with docetaxel sensitivity in lung cancerTatsuya Yoshimasu, Shoji Oura, Fuminori Ohta, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 17, 2012
[The importance of p53 and ras mutation as predictive markers for adjuvant chemotherapy in non-small-cell lung cancer]Yoshimitsu Hirai, Yukio Shimizu, Shoji Oura, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|February 19, 2009
[Safety and efficacy of weekly paclitaxel followed by FEC100 as primary systemic therapy for breast cancer]Koma Naito, Shoji Oura, Tatsuya Yoshimasu, et al.Clinical Breast Cancer|October 29, 2017
Radiofrequency Ablation of Breast Cancer: A Retrospective StudyToshikazu Ito, Shoji Oura, Shinji Nagamine, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 21, 2018
[Application of Bevacizumab beyond Progressive Disease in Patients with Lung Cancer Recurrence after Surgery]Tatsuya Yoshimasu, Shoji Oura, Mitsumasa Kawago, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 29, 2004
[Histoculture drug response assay for solitary fibrous tumor--a case report]Tatsuya Yoshimasu, Shoji Oura, Issei Hirai, et al.Cancer Science|February 18, 2004
Increased expression of integrin alpha3beta1 in highly brain metastatic subclone of a human non-small cell lung cancer cell lineTatsuya Yoshimasu, Teruhisa Sakurai, Shoji Oura, et al.Cancer|January 19, 2012
Ipsilateral breast tumor recurrence (IBTR) in patients with operable breast cancer who undergo breast-conserving treatment after receiving neoadjuvant chemotherapy: risk factors of IBTR and validation of the MD Anderson Prognostic IndexMakoto Ishitobi, Shozo Ohsumi, Hideo Inaji, et al.Breast Cancer Research and Treatment|December 23, 2016
Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trialDaigo Yamamoto, Nobuaki Sato, Yoshiaki Rai, et al.Pageof 14